<DOC>
	<DOCNO>NCT02746991</DOCNO>
	<brief_summary>This phase 3 , multi-national , multi-center , randomize , mask , control study evaluate safety efficacy injectable fluocinolone acetonide intravitreal ( FAI ) insert management subject chronic non-infectious uveitis affect posterior segment eye . Patients randomize receive either sham injection FAI insert observe three year follow treatment .</brief_summary>
	<brief_title>Safety Efficacy Study Fluocinolone Acetonide Intravitreal ( FAI ) Insert Subjects With Chronic Non-infectious Posterior Uveitis</brief_title>
	<detailed_description />
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Panuveitis</mesh_term>
	<mesh_term>Uveitis , Posterior</mesh_term>
	<mesh_term>Uveitis , Intermediate</mesh_term>
	<mesh_term>Pars Planitis</mesh_term>
	<mesh_term>Fluocinolone Acetonide</mesh_term>
	<criteria>Male non pregnant female least 18 year age time consent One eye history recurrent noninfectious uveitis affect posterior segment eye without anterior uveitis &gt; 1 year duration At time enrollment ( Day 1 ) , study eye &lt; 10 anterior chamber cells/HPF vitreous haze ≤ grade 2 . Visual acuity study eye least 15 letter ETDRS chart Subject planning undergo elective ocular surgery study Subject ability understand sign Informed Consent Form Subject willing able comply schedule visit , treatment plan , laboratory test study procedure During 12 month prior enrollment ( Day 1 ) , study eye either received treatment : systemic corticosteroid systemic therapy give least 3 month , and/or least 2 intra periocular administration corticosteroid management uveitis OR study eye experience recurrence : • least 2 separate recurrence uveitis require systemic , intra periocular injection corticosteroid Allergy fluocinolone acetonide component FAI insert History posterior uveitis accompany vitritis macular edema History iritis vitreous cell , anterior chamber cell vitreous haze Uveitis infectious etiology Vitreous hemorrhage Intraocular inflammation associate condition noninfectious uveitis ( e.g . intraocular lymphoma ) Ocular malignancy either eye , include choroidal melanoma Toxoplasmosis scar study eye scar relate previous viral retinitis Previous viral retinitis Current viral disease cornea conjunctiva include epithelial herpes simplex keratitis ( dendritic keratitis ) , vaccinia , varicella , mycobacterial infection eye fungal disease ocular structure Media opacity preclude evaluation retina vitreous Peripheral retinal detachment area insertion Diagnosis form glaucoma ocular hypertension study eye Screening , unless study eye previously treat incisional surgery procedure result stable IOP normal range ( 1021 mmHg ) Intraocular pressure ( IOP ) &gt; 21 mmHg concurrent therapy Screening IOPlowering pharmacologic agent study eye Chronic hypotony ( &lt; 6 mmHg ) Ocular surgery study eye within 3 month prior study Day 1 Capsulotomy study eye within 30 day prior study Day 1 Prior intravitreal treatment study eye Retisert within 36 month prior study Day 1 Prior intravitreal treatment study eye Ozurdex within 6 month prior study Day 1 Prior intravitreal treatment study eye Triesence Trivaris within 3 month prior study Day 1 Prior periocular subtenon steroid treatment study eye within 3 month prior study Day 1 Subjects require chronic systemic inhale corticosteroid therapy ( &gt; 15mg prednisone daily ) chronic systemic immunosuppressive therapy Excluding certain skin cancer ( specifically , basal cell carcinoma squamous cell carcinoma ) , malignancy receive treatment , remission le 5 year prior study Day 1 Subjects test positive human immune deficiency virus ( HIV ) , tuberculosis syphilis Systemic infection within 30 day prior study Day 1 Any severe acute chronic medical psychiatric condition could increase risk associate study participation could interfere interpretation study result , judgment investigator , could make subject inappropriate entry study Any systemic ocular condition , judgment investigator , could make subject inappropriate entry study Treatment investigational drug device within 30 day prior study Day 1 Pregnant nursing female ; female childbearing potential unwilling unable use acceptable method contraception outline protocol least 14 day prior study Day 1 Month 12 Visit Subjects unlikely comply study protocol likely lose followup within three year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>